Artificial intelligence is bringing Alzheimer's assessment closer to the stage when doctors need it most: the first signs of cognitive decline. Blood biomarkers are being combined with genetic risk and neuropsychological data to estimate whether mild cognitive impairment may progress to dementia. The approach looks beyond signs of disease in the brain to forecast how an individual patient’s condition may develop.
That distinction matters in Spain, where Alzheimer's disease accounts for 60% to 70% of dementia cases. Alzheimer Europe estimates that 983,920 people were living with dementia in the country in 2025, around 2.05% of the population. Across the European Union, more than 9 million people were estimated to be living with dementia in 2025; that figure could exceed 14.3 million by 2050.
A parallel line of research suggests that blood-based p-tau181 may help forecast future cognitive problems up to six years before they become evident, as reported by ScienceAlert.
ADmit Therapeutics built the technology around MAP-AD®, which carries CE-IVDR marking. It is designed to predict whether mild cognitive impairment will progress to dementia due to Alzheimer's disease. The test combines blood biomarkers based on mitochondrial DNA methylation with ApoE genotype, age and neuropsychological assessment. Next Generation Sequencing and Machine Learning process the information together. Reports published by Libertad Digital and Democrata on 21 September 2026 describe MAP-AD as an in vitro diagnostic product being promoted for use in Europe, rather than a laboratory prototype.
The test targets the uncertain period when symptoms have appeared but their course remains unclear.
For patients and clinicians, the forecast adds information that conventional disease markers cannot provide on their own. Marta Barrachina, CEO and co-founder of ADmit Therapeutics and a representative of the AseBio partner company, says amyloid plaques do not explain the full clinical complexity of every patient. Her company's approach considers biological processes, including energy regulation alongside inflammatory and immune activity, as well as genetic and clinical information. It does not treat brain pathology as the only explanation.
Blood-based p-tau217 tests are a related but distinct development. Cleveland Clinic Consult QD describes Elecsys Phospho-Tau (217P) Plasma as a potential triage tool for the Alzheimer’s diagnostic pathway. Recent dementia research summaries also highlight p-tau217 as a way to select participants for studies and prevention programs.
This wider model addresses a long-running problem in Alzheimer's research: some patients may have beta-amyloid plaques without later developing dementia. That makes it harder to sort participants accurately in clinical trials. Markers linked to cognitive progression could help researchers separate patient groups more precisely and assess treatments against a clearer clinical trajectory. Emerging p-tau217 research points in the same direction. Researchers are studying biomarker testing to detect Alzheimer's pathology and guide the next step in diagnosis, research or prevention.
The subject has also been covered in coverage of Alzheimer's prevalence in Spain. The growing burden of dementia gives these tools a clear public-health rationale. Clinicians should interpret the tests as part of an assessment, not as a standalone prediction of one person's future.
